Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection

van Marle, Guido; Church, Deirdre L; Nunweiler, Kali D; Cannon, Kris; Wainberg, Mark A; Gill, M John

doi:10.1186/1742-4690-7-74

Table 2 Drug resistance mutations by tissue source

From: Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection

Patient #7	PBL	Esophagus	Stomach	Duodenum	Colon
Visit 1
	None (100%)	None (20%)	None (25%	ND	ND
ddI		*T215Y* (20%)	L74V (8.3%)
		*M41L, T215Y* (40%)	*T215Y* (16.7%)
		*M41L, T69N, T215Y* (20%)	L74V, *T215Y* (50%)
Visit 2
	*M41L, L74V, T215Y* (100%)	*T215Y* (100%)	None (45.5%)	*M41L, T215Y*(54.5%)	*M41L*(33.3%)
ddI			*M41L, L74V, T215Y* (9.1%)	*T215Y* (27.3%)	L210W, *T215Y*(22.2%)
			*T215Y* (36.4%)	*M41L, L74V, T215Y* (18.2%)	None (44.4%)
			L74V, *T215Y* (9.1%)
Visit 3
	None (87.5%)	*M41L* (42.9%)	*T215Y*(93.8%)	*M41L* (18.2%)	*M41L, L210W, T215Y*(71.4%)
AZT	F77S (12.5%)	*T215Y* (57.1%)	L210F, *T215Y*(6.25%)	None (81.8%)	*M41L* (14.3%)
					*M41L*, V75G (14.3%)
Visit 2007
	None (100%)
HAART
Patient #60	PBL	Esophagus	Stomach	Duodenum	Colon
Visit 1
	D67N, K70R, *T215Y*, K219Q (80%)	None (90%)	None (8.3%)	D67N, T69N, K70R, K219Q (100%)	D67N, K70R, K219Q (30%)
AZT	D67N, K70R, K219Q (20%)	E44K (10%)	*M41L* (8.3%)		D67N, T69N, K70R, K219Q (50%)
			K70R, *T215Y*(83.3%)		D67N, T69N, K70R, F116V, K219Q (10%)
					E44V, D67N, T69N, K70R, K219Q (10%)
Visit 2
	None 100%	D67N, T69N, K70R, K219Q (90%)	K70R, *T215F* (10%)	D67N, K70R, K219Q (50%)	D67N, K70R, *T215Y*, K219Q (40%)
AZT		K70R, *T215Y* (10%)	D67N, T69N, K70R, K219Q (10%)	D67N, T69N, K70R, K219Q (50%)	D67N, T69D, K70R, *T215Y*, K219Q (60%)
			K70R, *T215Y* (80%)
Visit 3
	None (90.9%)	D67N, T69N, K70R, K219Q (10%)	ND	None (45.5%)	M184T (15.4%)
ddI	M41T (9.1%)	D67G, K70R, *T215Y* (10%)		K70R, *T215Y*(18.2%)	D67N, T69D, K70R, *T215F*, K219Q (76.9%)
		D67N, K70R, K219Q (10%)		K70R, *T215Y*, K219Q (9.1%)	D67N, T69D, K70R, V75I, *T215F*, K219Q (7.7%)
		K70R, *T215Y* (70%)		D67N, K70R, *T215Y*, K219Q (9.1%)
				D67N, T69D, K70R, *T215Y*, K219Q (9.1%)
				D67N, T69N, K70R, *T215Y*, K219Q (9.1%)
Patient #19	PBL	Esophagus	Stomach	Duodenum	Colon
Visit 1
	M41I, E44K, D67N, L74V (100%)	K70R (10%)	M41I, E44K, D67N, L74V (40%)	ND	ND
AZT		E44G (10%)	None (60%)
		F77S (10%)	None (60%)
		D67N, K70R, V118I, *T215Y*, K219Q (10%)
Visit 2
	*M41L, T215Y* (100%)	None (77.8%)	*T215Y* (100%)	None (50%)	F116K (14.3%)
AZT		D67G (11.1%)		L74V (50%)	None (85.7%)
		T215A (11.1%)
Visit 3
	*T215Y*(20%)	*M41L, T215Y* (100%)	None (25%)	None (77.8%)	*M41L, L74V, T215Y* (66.7%)
AZT	*M41L, T215Y* (80%)		K70R (50%)	*T215Y* (11.1%)	None (33.3%)
			L210W, *T215Y* (16.7%)	*M41L*, D67G (11.1%)
			*M41L, L210W, T215Y* (8.3%)
Visit 2007
	None (81.8%)
HAART	*M41L*, E44D, T215C (18.2%)
Patient #42	PBL	Esophagus	Stomach	Duodenum	Colon
Visit 1
	D67N, K70R, V118I, *T215Y*, K219Q (70%)	K70R, *T215Y*(100%)	None (58.3%)	M184T (9.1%)	D67N, K70R, V118I, *T215F*, K219Q (100%)
none	D67N, K70R, V118I, L210F, *T215F*, K219Q (10%)		D67N, K70R, V118I, *T215Y*, K219Q (41.7%)	D67N, T69D, K70R, *T215F*, K219Q (45.5.%)
	D67N, K70R, F116Y, V118I, *T215F*, K219Q (10%)			None (45.5%)
	E44D, D67N, K70R, V118I, *T215F*, K219Q (10%)

*ND - no viral sequences detected. Primary drug resistance mutations associated with high levels of drug resistance indicated in italics

Back to article page

ISSN: 1742-4690

Contact us

Submission enquiries: journalsubmissions@springernature.com

Retrovirology

Contact us